Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy. Now, results from the international Phase I clinical trial show that the device has the potential to significantly reduce rectal injury, a side effect caused by unwanted radiation exposure that can leave men with compromised bowel function following treatment.
Results of the 27-patient prospective trial were recently published in the Journal of Radiation Oncology. The device known as the BioProtect Balloon Implant was tested on patients with localized prostate cancer. It is designed to reduce radiation exposure to the rectum by expanding to increase the space between the rectum and the prostate. It remains in place throughout the treatment process and is designed to biodegrade completely within six months.
"We found that the addition of BioProtect reduced the radiation dose delivered to the rectum by an average of about 30 percent," says local primary investigator Mitchell Anscher, M.D., Florence and Hyman Meyers Chair of Radiation Oncology at VCU Massey Cancer Center. "Most notable was the device's ability to reduce exposure at higher radiation levels, which indicates that the cancer could be safely treated with more aggressive protocols."
The researchers observed a greater reduction in radiation exposure to the rectum at increasing radiation dose levels. At 50 percent of prescribed dose, there was little difference in rectal tissue exposure. However, there was a 55.3 percent reduction at 70 percent of the prescribed dosage, a 64 percent reduction at 80 percent of the prescribed dosage, a 72 percent reduction at 90 percent of the prescribed dosage and an 82.3 percent reduction at 100 percent of the prescribed dosage.
As anticipated, all implanted balloons started to degrade three months after implantation. The researchers concluded that the device could be especially useful in hypofractionated radiation therapy. Hypofractionated radiation therapy uses larger doses of radiation applied over a shorter number of treatments instead of delivering a small percentage of the total dose during daily treatments spread over a longer period of time.
"Massey has many patients that travel from rural areas for care. If this device allows us to deliver the prescribed radiation dose over a shorter period of time, we can reduce the overall burden on the patient and they can spend less time away from work and their family," says Anscher. "We hope to initiate a Phase II clinical trial in a larger cohort of patients in order to determine the effectiveness of the device in reducing rectal injury in comparison to standard treatment protocols."
Anscher collaborated with the study's lead investigator Gyorgy Kovacs, M.D., Ph.D., from the University of Lubeck, Germany; Dieter Jocham, M.D., and Gunther Bohlen, M.D., also from the University of Lubeck; Eliahu Gez, M.D., Rami Ben Yosef, M.D., Benjamin W. Corn, M.D., and Fabrizio Dal Moro, M.D., all from the Department of Radiation Oncology at Tel Aviv Sourasky Medical Center, Israel; Giovanni Scarzello, M.D., from the Department of Radiotherapy at the University of Padova, Italy; and Isaac Koziol, M.D., Mathew Bassignani, M.D., and Taryn Torre, M.D., all from Virginia Urology; and Shmuel Cytron, M.D., from Barzilai Medical Center, Israel.
This research was supported, in part, by funding from VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
The full manuscript of the study is available online at:
Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 67 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at http://www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.vcu.edu.
John Wallace | EurekAlert!
Rare neurological disease shines light on health of essential nerve cells
23.01.2015 | University of Wisconsin-Madison
Dragnet for epilepsy genes
23.01.2015 | Rheinische Friedrich-Wilhelms-Universität Bonn
19.01.2015 | Event News
19.01.2015 | Event News
22.12.2014 | Event News
23.01.2015 | Health and Medicine
23.01.2015 | Ecology, The Environment and Conservation
23.01.2015 | Physics and Astronomy